Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHUK | O15111 | 13/20 | 0.38 |
| ▸ | IKBKB | O14920 | 3/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.34 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.31 |
| ▸ | IRAK3 | Q9Y616 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3391685 | 0.80 | CHUK (0.54) | CHUKIKBKBIRAK4 | |
| SCHEMBL11986721 | 0.77 | CHUK (0.41) | CHUKIKBKB | |
| SCHEMBL13539637 | 0.76 | CHUK (0.35) | CHUKIRAK4 | |
| SCHEMBL15618411 | 0.76 | IRAK4 (0.47) | IRAK4IRAK1IRAK3 | |
| SCHEMBL24811750 | 0.74 | CHEK1 (0.41) | CHUKIKBKB | |
| SCHEMBL12430388 | 0.73 | CHUK (0.38) | CHUKIKBKBIRAK4 | |
| SCHEMBL17175013 | 0.73 | DHFR (0.33) | — | |
| SCHEMBL24630170 | 0.73 | CHUK (0.40) | CHUKIKBKB | |
| SCHEMBL3391755 | 0.69 | DYRK1A (0.42) | — | |
| SCHEMBL10198718 | 0.67 | IRAK4 (0.48) | IRAK4IRAK1IRAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| EP-1809292-B1 | CONDENSED PYRIMIDINE DERIVATIVES AS INHIBITORS OF FOIC ACID-DEPENDENT ENZYMES | STOICESCU DAN (CH) | 2008-05-21 | — | — | EP | disclosed |
| WO-2007020277-A2 | CONDENSED PYRIMIDINE DERIVATIVES AS INHIBITORS OF FOIC ACID-DEPENDENT ENZYMES | STOICESCU DAN (CY) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | HAVCR2, FCGR3B, FCGR2A | CHUK 2864/4885IKBKB 1573/4885IRAK4 1772/4885 |
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | HAVCR2, ASGR1, FCGR3B | CHUK 2853/4885IKBKB 1642/4885IRAK4 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.